Note: CDD trials don’t rout inely collect data on race. Ethnicity information is collected for some trials, where ethnicity information is collected, the standard category of Race will be entered as “not collected” (or equivalent) on C linicalT rials.gov and Ethnicity information provided as an additional baseline measure. Arm/Group Title Experimental: AST -VAC2 Arm/Group Description Participants will receive up to a maximum of six vaccinations over six weeks. Each weekly AST -VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 x 107 viable cells. There is no dose escalation planned during the study; only one dose level will be explored. Overall Baseline Participants Number of Participants Baseline Analysis Population Description * Age, Number Analysed Age, Median (Full range) Sex, Number Analysed Male, number of participants Female, number of participants Ethnicity Not collected SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 32 7.4 Reported Adverse Events (clinicaltrials.gov template sections) AE Reporting Timeframe: Safety data will be collected from the time of informed consent until 2 years from the first dose of AST -VAC2 for this interim report . Patients are followed -up for 5 years; if there are any changes to information reported at end of trial, this will be updated.